Chitosan-zinc-insulin complex incorporated thermosensitive polymer for controlled delivery of basal insulin in vivo

Journal of Controlled Release

Volumn 163, Issue 2, 2012, Pages 145-153

  Oak, Mayura ^a   Singh, Jagdish ^a  

^a NORTH DAKOTA STATE UNIVERSITY   (United States)

Author keywords

Biocompatibility; Chitosan zinc insulin complex; Controlled release; In vivo release and bioactivity; Insulin; Protein delivery

Indexed keywords

BASAL LEVELS; BLOOD GLUCOSE LEVEL; BURST RELEASE; CHITOSAN-ZINC-INSULIN COMPLEX; CONTROLLED DELIVERY; CONTROLLED RELEASE; DELIVERY SYSTEMS; DIABETIC RATS; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNE RESPONSE; IN-VITRO; IN-VIVO; INSULIN DELIVERY; INSULIN THERAPY; MTT ASSAYS; PLA-PEG-PLA; POLYMERIC DELIVERY SYSTEMS; PROTEIN DELIVERY; SKIN SAMPLES; STREPTOZOTOCIN; THERMO SENSITIVE; THERMO-SENSITIVE POLYMER;

BIOACTIVITY; BIOCOMPATIBILITY; BLOOD; CHITOSAN; GLUCOSE; POLYMERS; POLYPEPTIDES; RATS; ZINC;

INSULIN;

CHITOSAN; CHITOSAN ZINC INSULIN COMPLEX; GLUCOSE; INSULIN; POLY(DEXTRO,LEVO LACTIDE) POLY(ETHYLENE GLYCOL) POLY(DEXTRO,LEVO LACTIDE); POLYMER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCOMPATIBILITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; GLUCOSE BLOOD LEVEL; HEAT SENSITIVITY; HISTOPATHOLOGY; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES;

ANIMALS; BLOOD GLUCOSE; CELL SURVIVAL; CHITOSAN; COLLAGEN; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, EXPERIMENTAL; DRUG DELIVERY SYSTEMS; HEK293 CELLS; HOT TEMPERATURE; HUMANS; INSULIN; MALE; POLYESTERS; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; SKIN; ZINC;

EID: 84866686290     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2012.07.035     Document Type: Article

References (61)

1. S. Adhikari, B. Adams-Huet, Y.-C.A. Wang, J.F. Marks, and P.C. White Institution of basal-bolus therapy at diagnosis for children with type 1 diabetes mellitus Pediatrics 123 4 2009 e673 e678
2. R. Guthrie Is there a need for a better basal insulin? Clin. Diab. 19 2 2001 66 70
3. Y.T. Kruszynska, P.D. Home, I. Hanning, and K.G. Alberti Basal and 24-h C-peptide and insulin secretion rate in normal man Diabetologia 30 1 1987 16 21 (Pubitemid 17017808)
4. R.G. Moses, P. Bartley, H. Lunt, R.C. O'Brien, T. Donnelly, M.-A. Gall, A. Vesterager, P. Wollmer, and A. Roberts Safety and efficacy of inhaled insulin (AERx® iDMS1) compared with subcutaneous insulin therapy in patients with Type 1 diabetes: 1-year data from a randomized, parallel group trial Diabet. Med. 26 3 2009 260 267
5. R. Jani, C. Triplitt, C. Reasner, and R.A. Defronzo First approved inhaled insulin therapy for diabetes mellitus Expert Opin. Drug Deliv. 4 1 2007 63 76 (Pubitemid 46117487)
6. TM) administered to healthy male volunteers J. Diabetes Sci. Technol. 2 6 2008 1054 1060
7. P. Modi, M. Mihic, and A. Lewin The evolving role of oral insulin in the treatment of diabetes using a novel RapidMist System Diabetes Metab. Res. Rev. 18 2002 S38 S42
8. R.P. Radermecker, E. Renard, and A.J. Scheen Circulating insulin antibodies: influence of continuous subcutaneous or intraperitoneal insulin infusion, and impact on glucose control Diabetes Metab. Res. Rev. 25 6 2009 491 501
9. K.J. Robertson, E. Schoenle, Z. Gucev, L. Mordhorst, M.-A. Gall, and J. Ludvigsson Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes Diabet. Med. 24 1 2007 27 34 (Pubitemid 46103068)
10. J.-C. Philips, and A. Scheen Insulin detemir in the treatment of type 1 and type 2 diabetes Vasc. Health Risk Manag. 2 3 2006 277 283 (Pubitemid 44275463)
11. S. Heller, C. Koenen, and B. Bode Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, Treat-to-Target noninferiority trial Clin. Ther. 31 10 2009 2086 2097
12. L.F. Meneghini, K.H. Rosenberg, C. Koenen, M.J. Merilainen, and H.-J. Lüddeke Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the predictive study Diabetes Obes. Metab. 9 3 2007 418 427 (Pubitemid 46502062)
13. I.B. Hirsch Insulin analogues N. Engl. J. Med. 352 2 2005 174 183 (Pubitemid 40096614)
14. K. Al-Tahami, M. Oak, R. Mandke, and J. Singh Basal level insulin delivery: in vitro release, stability, biocompatibility, and in vivo absorption from thermosensitive triblock copolymers J. Pharm. Sci. 100 11 2011 4790 4803
15. C. Manoharan, and J. Singh Evaluation of polyanhydride microspheres for basal insulin delivery: effect of copolymer composition and zinc salt on encapsulation, in vitro release, stability, in vivo absorption and bioactivity in diabetic rats J. Pharm. Sci. 98 11 2009 4237 4250
16. D.P. Huynh, M.K. Nguyen, B.S. Pi, M.S. Kim, S.Y. Chae, K.C. Lee, B.S. Kim, S.W. Kim, and D.S. Lee Functionalized injectable hydrogels for controlled insulin delivery Biomaterials 29 16 2008 2527 2534
17. S. Choi, and S.W. Kim Controlled release of insulin from injectable biodegradable triblock copolymer depot in ZDF rats Pharm. Res. 20 12 2003 2008 2010 (Pubitemid 38005533)
18. K. Al-Tahami, and J. Singh Smart polymer based delivery systems for peptides and proteins Recent Pat. Drug Deliv. Formul. 1 1 2007 65 71
19. N.B. Phillips, Z. Wan, L. Whittaker, S.-Q. Hu, K. Huang, Q.X. Hua, J. Whittaker, F. Ismail-Beigi, and M.A. Weiss Supramolecular protein engineering, design of zinc-stapled insulin hexamers as a long acting depot J. Biol. Chem. 285 16 2010 11755 11759
20. M.F. Dunn Zinc-ligand interactions modulate assembly and stability of the insulin hexamer - a review Biometals 18 4 2005 295 303 (Pubitemid 41298012)
21. B. Luppi, F. Bigucci, L. Mercolini, A. Musenga, M. Sorrenti, L. Catenacci, and V. Zecchi Novel mucoadhesive nasal inserts based on chitosan/hyaluronate polyelectrolyte complexes for peptide and protein delivery J. Pharm. Pharmacol. 61 2 2009 151 157
22. A. Jintapattanakit, P. Peungvicha, A. Sailasuta, T. Kissel, and V.B. Junyaprasert Nasal absorption and local tissue reaction of insulin nanocomplexes of trimethyl chitosan derivatives in rats J. Pharm. Pharmacol. 62 5 2010 583 591
23. A. Jintapattanakit, V.B. Junyaprasert, S. Mao, J. Sitterberg, U. Bakowsky, and T. Kissel Peroral delivery of insulin using chitosan derivatives: a comparative study of polyelectrolyte nanocomplexes and nanoparticles Int. J. Pharm. 342 1-2 2007 240 249 (Pubitemid 47259332)
24. A. Jintapattanakit, V.B. Junyaprasert, and T. Kissel The role of mucoadhesion of trimethyl chitosan and PEGylated trimethyl chitosan nanocomplexes in insulin uptake J. Pharm. Sci. 98 12 2009 4818 4830
25. S. Mao, U. Bakowsky, A. Jintapattanakit, and T. Kissel Self-assembled polyelectrolyte nanocomplexes between chitosan derivatives and insulin J. Pharm. Sci. 95 5 2006 1035 1048 (Pubitemid 43723163)
26. Y. Jin, D. Zhou, H.-Y. Yang, X. Zhu, X.-R. Wang, Z.-R. Zhang, and Y. Huang Effects of degree of quaternization on the preparation and characterization of insulin-loaded trimethyl chitosan polyelectrolyte complexes optimized by central composite design Pharm. Dev. Technol. 2011 ([Epub ahead of print])
27. M. Oak, and J. Singh Controlled delivery of basal level of insulin from chitosan-zinc-insulin-complex-loaded thermosensitive copolymer J. Pharm. Sci. 101 3 2012 1079 1096
28. Mercodia-Insulin ELISA kit Manual http://www.mercodia.se/ 2011
29. S. Gupta, T. Chattopadhyay, M. Pal Singh, and A. Surolia Supramolecular insulin assembly II for a sustained treatment of type 1 diabetes mellitus Proc. Natl. Acad. Sci. U. S. A. 107 30 2010 13246 13251
30. K. Al-Tahami, M. Oak, and J. Singh Controlled delivery of basal insulin from phase-sensitive polymeric systems after subcutaneous administration: in vitro release, stability, biocompatibility, in vivo absorption, and bioactivity of insulin J. Pharm. Sci. 100 6 2011 2161 2171
31. M. Rowland, and T.N. Tozer Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications Fourth ed. 2010 Lippincott Williams & Wilkins
32. P.G. Shao, and L.C. Bailey Stabilization of pH-induced degradation of porcine insulin in biodegradable polyester microspheres Pharm. Dev. Technol. 4 4 1999 633 642 (Pubitemid 29536085)
33. S. Sajeesh, and C.P. Sharma Novel pH responsive polymethacrylic acid-chitosan-polyethylene glycol nanoparticles for oral peptide delivery J. Biomed. Mater. Res. A 76B 2 2006 298 305 (Pubitemid 43165387)
34. R. Mandke, and J. Singh Effect of acyl chain length and unsaturation on physicochemical properties and transfection efficiency of N-acyl-substituted low-molecular-weight chitosan J. Pharm. Sci. 101 1 2012 268 282
35. K.K. Wu, and Y. Huan Streptozotocin-induced diabetic models in mice and rats Curr. Protoc. Pharmacol. 40 2008 5.47.1 5.47.14
36. J.M. Barichello, M. Morishita, K. Takayama, and T. Nagai Absorption of insulin from Pluronic F-127 gels following subcutaneous administration in rats Int. J. Pharm. 184 2 1999 189 198 (Pubitemid 29317652)
37. R.A. Rizza, L.J. Mandarino, and J.E. Gerich Dose-response characteristics for effects of insulin on production and utilization of glucose in man Am. J. Physiol. 240 6 1981 E630 E639
38. M. Takenaga, Y. Yamaguchi, A. Kitagawa, Y. Ogawa, Y. Mizushima, and R. Igarashi A novel insulin formulation can keep providing steady levels of insulin for much longer periods in-vivo J. Pharm. Pharmacol. 54 9 2002 1189 1194
39. J. Li, and J.D. Johnson Mathematical models of subcutaneous injection of insulin analogues: a mini-review Discrete Continuous Dyn. Syst. Ser. B 12 2 2009 401 414
40. P. Calvo, C. Remuñan-López, J.L. Vila-Jato, and M.J. Alonso Chitosan and chitosan/ethylene oxide-propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines Pharm. Res. 14 10 1997 1431 1436 (Pubitemid 27481075)
41. P. Calvo, C. Remuñán-López, J.L. Vila-Jato, and M.J. Alonso Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers J. Appl. Polym. Sci. 63 1 1997 125 132 (Pubitemid 127613982)
42. A. Vila, A. Sánchez, K. Janes, I. Behrens, T. Kissel, J.L. Vila Jato, and M.J. Alonso Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice Eur. J. Pharm. Biopharm. 57 1 2004 123 131 (Pubitemid 38058811)
43. R. Fernández-Urrusuno, P. Calvo, C. Remuñán- López, J.L. Vila-Jato, and M. Alonso Enhancement of nasal absorption of insulin using chitosan nanoparticles Pharm. Res. 16 10 1999 1576 1581 (Pubitemid 29510555)
44. R. Leonardi, J.E. Rehg, C.O. Rock, and S. Jackowski Pantothenate kinase 1 is required to support the metabolic transition from the fed to the fasted state PLoS One 5 6 2010 1 12
45. Y.M. Kwon, and S.W. Kim Biodegradable triblock copolymer microspheres based on thermosensitive sol-gel transition Pharm. Res. 21 2 2004 339 343 (Pubitemid 38221981)
46. International Diabetes Federation The global burden: diabetes and impaired glucose tolerance (IGT): prevalence and projections IDF Diabetes Atlas 4th ed. 2011 International Diabetes Federation Brussels
47. C. Veeramani, G. Pushpavalli, and K. Pugalendi Antihyperglycaemic effect of Cardiospermum halicacabum Linn. leaf extract on STZ-induced diabetic rats J. Appl. Biomed. 6 1 2007 19 26
48. S. Hermeling, D.J.A. Crommelin, H. Schellekens, and W. Jiskoot Structure-immunogenicity relationships of therapeutic proteins Pharm. Res. 21 6 2004 897 903 (Pubitemid 38870136)
49. G. Schernthaner Immunogenicity and allergenic potential of animal and human insulins Diabetes Care 16 Suppl. 3 1993 155 165 (Pubitemid 23348330)
50. S.E. Fineberg, T.T. Kawabata, D. Finco-Kent, R.J. Fountaine, G.L. Finch, and A.S. Krasner Immunological responses to exogenous insulin Endocr. Rev. 28 6 2007 625 652 (Pubitemid 47606649)
51. R. Riva, H. Ragelle, A. des Rieux, N. Duhem, C. Jerome, and V. Preat Chitosan and chitosan derivatives in drug delivery and tissue engineering Adv. Polym. Sci. 244 2011 19 44
52. T. Kean, and M. Thanou Biodegradation, biodistribution and toxicity of chitosan Adv. Drug Deliv. Rev. 62 1 2010 3 11
53. S. Mansouri, P. Lavigne, K. Corsi, M. Benderdour, E. Beaumont, and J.C. Fernandes Chitosan-DNA nanoparticles as non-viral vectors in gene therapy: strategies to improve transfection efficacy Eur. J. Pharm. Biopharm. 57 1 2004 1 8 (Pubitemid 38058799)
54. U.S. Environmental Protection Agency Washington D.C. Toxicological Review of Zinc and Compounds 2005 CAS No. 7440-66-6.
55. A.A. Ignatius, and L.E. Claes In vitro biocompatibility of bioresorbable polymers: poly(l, dl-lactide) and poly(l-lactide-co-glycolide) Biomaterials 17 8 1996 831 839 (Pubitemid 26108352)
56. G.A. Silva, A.P. Marques, M.E. Gomes, O.P. Coutinho, and R.L. Reis Cytotoxicity screening of biodegradable polymeric systems R.L. Reis, J.S. Román, Biodegradable Systems in Tissue Engineering and Regenerative Medicine 2004 CRC Press LLC 339 353
57. N. Nwe, T. Furuike, and H. Tamura The mechanical and biological properties of chitosan scaffolds for tissue regeneration templates are significantly enhanced by chitosan from Gongronella butleri Materials 2 2 2009 374 398
58. J.M. Morais, F. Papadimitrakopoulos, and D.J. Burgess Biomaterials/tissue interactions: possible solutions to overcome foreign body response AAPS J. 12 2 2010 188 196
59. Y. Onuki, U. Bhardwaj, F. Papadimitrakopoulos, and D.J. Burgess A review of the biocompatibility of implantable devices: current challenges to overcome foreign body response J. Diabetes Sci. Technol. 2 6 2008 1003 1015
60. T.G. Park, W. Lu, and G. Crotts Importance of in vitro experimental conditions on protein release kinetics, stability and polymer degradation in protein encapsulated poly(d,l-lactic acid-co-glycolic acid) microspheres J. Control. Release 33 2 1995 211 222
61. A.L. Daugherty, J.L. Cleland, E.M. Duenas, and R.J. Mrsny Pharmacological modulation of the tissue response to implanted polylactic-co-glycolic acid microspheres Eur. J. Pharm. Biopharm. 44 1 1997 89 102 (Pubitemid 28298779)